Therefore, LMP2A can also enhance B-cell APC function by activating TLR9, which activates the body’s immune response, promotes inflammation, releases inflammatory factor IFNγ, and further aggravates MS progression (Figure 1C) (Chang et al., 2012). Here, IFNG is linked to myeloid sarcoma.